ONCAlert | 2017 San Antonio Breast Cancer Symposium

Results of the Phase III APHINITY Trial in HER2-Positive Breast Cancer

Gunter von Minckwitz, MD, PhD
Published Online:3:23 PM, Wed July 5, 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses results from the large phase III APHINITY trial, which explored the addition of pertuzumab (Perjeta) to adjuvant trastuzumab and chemotherapy for patients with HER2-positive early breast cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.